Management of OSA in Heart Failure Patient Refusing CPAP and MAD with Elevated Hematocrit
In a heart failure patient who refuses both CPAP and mandibular advancement devices and had elevated hematocrit with the oral appliance, you should pursue hypoglossal nerve stimulation (HNS) if the patient meets STAR trial criteria, or consider maxillomandibular osteotomy (MMO) as surgical alternatives, while simultaneously optimizing heart failure therapy and addressing weight management. 1
Algorithmic Approach to This Complex Case
Step 1: Understand the Elevated Hematocrit Context
The elevated hematocrit during MAD use likely reflects untreated or inadequately treated OSA rather than a complication of the device itself. OSA causes chronic intermittent hypoxia, which stimulates erythropoietin production and secondary polycythemia—occurring in approximately 6% of severe OSA cases 2. The hematocrit elevation indicates the OSA remains physiologically significant and requires effective treatment.
Step 2: Evaluate for Hypoglossal Nerve Stimulation
HNS should be your primary consideration if the patient meets specific criteria from the STAR trial 1:
- Moderate to severe OSA (AHI 15-65 events/hour)
- BMI ≤32 kg/m²
- Failed or cannot tolerate CPAP
- No complete concentric collapse at the palate on drug-induced sleep endoscopy
The 2021 ERS guideline provides a conditional recommendation for HNS specifically in symptomatic OSA patients who have failed or not tolerated CPAP 1. Recent multidisciplinary data shows significant improvements with HNS: AHI reductions of 44.1%, ESS reductions of 32.9%, and ODI reductions of 67.2% in appropriately selected patients 3.
Step 3: Consider Maxillomandibular Osteotomy
If HNS is not feasible (anatomically unsuitable, patient preference, or resource limitations), MMO represents an effective alternative for CPAP-intolerant patients 1. This surgical option permanently enlarges the upper airway and can be highly effective in selected cases.
Step 4: Optimize Heart Failure Management Concurrently
Critical for this patient: Optimization of fluid balance and standard HF medications may help minimize OSA severity 4. The bidirectional relationship between HF and OSA means that improving cardiac function can reduce central and obstructive respiratory events. This is particularly important given that treating OSA in HF patients improves cardiac function and lowers sympathetic activity 5.
Step 5: Implement Weight Management Strategy
If BMI is elevated, aggressive weight management should be prioritized 1, 3. Weight loss can significantly reduce OSA severity and may improve candidacy for HNS if BMI is currently above threshold. Bariatric surgery can be considered in appropriate candidates 6.
Step 6: Consider Adjunctive Therapies
Positional therapy (if position-dependent OSA) using vibratory devices can be added 1. Myofunctional therapy may provide modest benefit as an adjunct 1.
Important Caveats and Pitfalls
The Hematocrit Issue
Do not interpret the elevated hematocrit as a contraindication to further OSA treatment—it is actually an indication that effective therapy is urgently needed 2. Once OSA is adequately treated, hemoglobin typically decreases by approximately 3.76 g/L and hematocrit by 1.1% 2.
Heart Failure Considerations
In HF patients, distinguish between obstructive and central sleep apnea, as management differs significantly 7, 8. If the patient has significant central sleep apnea component, adaptive servo-ventilation (ASV) may be considered, though this requires careful patient selection and should not be used in patients with HF with reduced ejection fraction and predominant CSA due to potential harm 7.
Access and Equity Issues
HNS involves significant cost and requires specialized expertise 1. Availability varies by healthcare system and geographic location. If not accessible, focus on surgical options (MMO) or combination approaches.
Multidisciplinary Coordination
Involve sleep medicine consultation, cardiology, and potentially ENT/maxillofacial surgery 9, 3. The complexity of HF with OSA, device intolerance, and physiological consequences (elevated hematocrit) necessitates coordinated specialty care.
Monitoring Strategy
Once alternative therapy is implemented:
- Repeat sleep study at 3 months to document AHI improvement
- Monitor hematocrit levels to confirm normalization with effective OSA treatment
- Assess cardiovascular outcomes: blood pressure, HF symptoms, arrhythmia burden
- Track patient-reported outcomes: Epworth Sleepiness Scale, quality of life measures
The goal is not just AHI reduction but improvement in cardiovascular function, symptoms, and ultimately mortality risk in this high-risk HF population 5, 8.